Results 191 to 200 of about 3,918,004 (266)

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

The Soifua Manuia reference panel with 2,570 Samoan haplotypes improves genotype imputation quality among Samoans. [PDF]

Commun Biol
Carlson JC, Krishnan M, Liu S, Anderson KJ, Zhang JZ, Spor LM, Yapp TJ, Chiyka EA, Dikec DA, Cheng H, Naseri T, Reupena MS, Viali S, Deka R, Hawley NL, McGarvey ST, Weeks DE, Minster RL.   +17 more
europepmc   +1 more source

References of references in Robotics. References of references in multi-fingered hand.

Journal of the Robotics Society of Japan, 1998
openaire   +2 more sources

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Inpatient medical costs and their composition among patients with stomach cancer who underwent surgery by tumor location: a hospital-based retrospective study in China. [PDF]

Cost Eff Resour Alloc
Hu ZB, Chen SQ, McDonald S, Chen MM, Yu H, Lin Y.   +5 more
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Factors Associated With the Syndromic Diagnosis of Sexually Transmitted Infections Among Adolescent Girls and Young Women (AGYW): Findings From the Namibia DREAMS Program. [PDF]

J Trop Med
Moyo E, Melese E, Mangwana H, Takawira S, Harases B, Indongo R, Moyo P, Nyoni NM, Dzinamarira T.   +8 more
europepmc   +1 more source